Cyclophosphamide versus placebo in scleroderma lung disease

Donald P. Tashkin*, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel E. Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster, James R. Seibold, David J. Riley, Vivien M. Hsu, John Varga, Dean E. Schraufnagel, Arthur Theodore, Robert Simms, Robert Wise, Fredrick Wigley, Barbara WhiteVirginia Steen, Charles Read, Maureen Mayes, Ed Parsley, Kamal Mubarak, M. Kari Connolly, Jeffrey Golden, Mitchell Olman, Barri Fessler, Naomi Rothfield, Mark Metersky

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1344 Scopus citations

Fingerprint

Dive into the research topics of 'Cyclophosphamide versus placebo in scleroderma lung disease'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

INIS

Immunology and Microbiology